Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen Divests Pain Assets to Depomed | Contract Pharma

What are you searching for?

Sign in
Breaking News

Janssen Divests Pain Assets to Depomed

Gains NUCYNTA product rights for $1.05 billion

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Janssen Pharmaceuticals, Inc. (JPI) has entered into a definitive agreement with Depomed to divest its U.S. rights to pain medications NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended-release tablets and NUCYNTA (tapentadol) oral solution, for $1.05 billion. The transaction, subject to customary closing conditions, is expected to close in 2Q15. With this strategic decision, JPI aims to focus efforts and resources on targeted growth priorities.  
 
JPI currently licenses the commercialization rights to the NUCYNTA products from Grunenthal GmbH. JPI will retain license rights in Canada, Japan, and a number of other countries outside the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters